Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Ironwood and Forest Laboratories Submit Linaclotide to FDA

By Drug Discovery Trends Editor | August 10, 2011

Ironwood Pharmaceuticals Inc. and Forest Laboratories Inc. have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for linaclotide, a guanylate cyclase type?C (GC?C) agonist, for the treatment of irritable bowel syndrome with constipation (IBS?C) and chronic constipation (CC).

Linaclotide, an investigational drug, is an agonist of the guanylate cyclase type?C (GC?C) receptor located on the luminal surface of the intestine. In preclinical models, linaclotide reduced visceral hypersensitivity, increased fluid secretion, and accelerated intestinal transit.

The submission includes efficacy and safety data from a Phase 3 program comprising four double?blind placebo?controlled trials and two open?label long term safety studies. More than 2,800 patients received a once?daily dose of either linaclotide or placebo across the four placebo?controlled clinical trials: two trials in patients with IBS?C and two trials in patients with CC.

In the trials, statistically significant improvements in abdominal and bowel symptoms were achieved for linaclotide?treated patients versus placebo?treated patients for all primary and
secondary endpoints. Safety data collected across the four placebo?controlled Phase 3 clinical trials demonstrated that diarrhea was the most commonly reported adverse event and led to study discontinuation in 4% to 5% of linaclotide?treated patients compared to fewer than 1% of patients receiving placebo.

Additionally, over 3,200 patients have enrolled in ongoing open?label safety studies and more than 1,100 of those patients have received linaclotide for at least 12 months.

Release Date: August 9, 2011
Source: Ironwood Pharmaceuticals, Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE